Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: a prospective observational study

Zahra Hasan; Kiran Iqbal Masood; Shama Qaiser; Erum Khan; Areeba Hussain; Zara Ghous; Unab Khan; Maliha Yameen; Imran Hassan; Muhammad Imran Nasir; Muhammad Farrukh Qazi; Haris Ali Memon; Shiza Ali; Sadaf Baloch; Zulfiqar A. Bhutta; Marc Veldhoen; J. Pedro Simas; Syed Faisal Mahmood; Kulsoom Ghias; Rabia Hussain

doi:10.1002/hsr2.1521

Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: a prospective observational study

Zahra Hasan^*, Kiran Iqbal Masood, Shama Qaiser, Erum Khan, Areeba Hussain, Zara Ghous, Unab Khan, Maliha Yameen, Imran Hassan, Muhammad Imran Nasir, Muhammad Farrukh Qazi, Haris Ali Memon, Shiza Ali, Sadaf Baloch, Zulfiqar A. Bhutta, Marc Veldhoen, J. Pedro Simas, Syed Faisal Mahmood, Kulsoom Ghias, Rabia Hussain

^*Autor correspondente para este trabalho

Resultado de pesquisa › revisão de pares

4 Citações (Scopus)

9 Transferências (Pure)

Resumo

Background and Aims: COVID-19 vaccinations have reduced morbidity and mortality from the disease. Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) have been associated with immune protection. Seroprevalence studies revealed high immunoglobulin G (IgG) antibody levels to SARS-CoV-2 in the Pakistani population before vaccinations. We investigated the effect of BBIBP-CorV vaccination on circulating IgG antibodies and interferon (IFN)-γ from T cells measured in a cohort of healthy individuals, with respect to age, gender, and history of COVID-19. Methods: The study was conducted between April and October 2021. BBIBP-CorV vaccinated participants were followed up to 24 weeks. Antibodies to SARS-CoV-2 Spike protein and its receptor-binding domain (RBD) were measured. IFNγ secreted by whole blood stimulation of Spike protein and extended genome antigens was determined. Results: Study participants with a history of prior COVID-19 displayed a higher magnitude of IgG antibodies to Spike and RBD. IgG seropositivity was greater in those with prior COVID-19, aged 50 years or younger and in females. At 24 weeks after vaccination, 37.4% of participants showed IFN-γ responses to SARS-CoV-2 antigens. T cell IFN-γ release was higher in those with prior COVID-19 and those aged 50 years or less. Highest IFN-γ release was observed to extended genome antigens in individuals both with and without prior COVID-19. Conclusion: We found that IgG seropositivity to both Spike and RBD was affected by prior COVID-19, age and gender. Importantly, seropositive responses persisted up to 24 weeks after vaccination. Persistence of vaccine induced IgG antibodies may be linked to the high seroprevalence observed earlier in unvaccinated individuals. Increased T cell reactivity to Spike and extended genome antigens reflects cellular activation induced by BBIBP-CorV. COVID-19 vaccination may have longer lasting immune responses in populations with a higher seroprevalence. These data inform on vaccination booster policies for high-risk groups.

Idioma original	English
Número do artigo	e1521
Número de páginas	11
Revista	Health Science Reports
Volume	6
Número de emissão	9
DOIs	https://doi.org/10.1002/hsr2.1521
Estado da publicação	Publicado - 8 set. 2023

ODS da ONU

Este resultado contribui para o(s) seguinte(s) Objetivo(s) de Desenvolvimento Sustentável

Acesso ao documento

10.1002/hsr2.1521Licença:

75214043Final published version, 1,48 MBLicença:

http://hdl.handle.net/10400.14/42685Licença:

Outros arquivos e links

Link to publication in Scopus

Impressão digital

Mergulhe nos tópicos de investigação de “Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: a prospective observational study“. Em conjunto formam uma impressão digital única.

Citação

Hasan, Z., Masood, K. I., Qaiser, S., Khan, E., Hussain, A., Ghous, Z., Khan, U., Yameen, M., Hassan, I., Nasir, M. I., Qazi, M. F., Memon, H. A., Ali, S., Baloch, S., Bhutta, Z. A., Veldhoen, M., Simas, J. P., Mahmood, S. F., Ghias, K., & Hussain, R. (2023). Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: a prospective observational study. Health Science Reports, 6(9), Artigo e1521. https://doi.org/10.1002/hsr2.1521

@article{682255b8315e4d61873818f3ab662da6,

title = "Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: a prospective observational study",

abstract = "Background and Aims: COVID-19 vaccinations have reduced morbidity and mortality from the disease. Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) have been associated with immune protection. Seroprevalence studies revealed high immunoglobulin G (IgG) antibody levels to SARS-CoV-2 in the Pakistani population before vaccinations. We investigated the effect of BBIBP-CorV vaccination on circulating IgG antibodies and interferon (IFN)-γ from T cells measured in a cohort of healthy individuals, with respect to age, gender, and history of COVID-19. Methods: The study was conducted between April and October 2021. BBIBP-CorV vaccinated participants were followed up to 24 weeks. Antibodies to SARS-CoV-2 Spike protein and its receptor-binding domain (RBD) were measured. IFNγ secreted by whole blood stimulation of Spike protein and extended genome antigens was determined. Results: Study participants with a history of prior COVID-19 displayed a higher magnitude of IgG antibodies to Spike and RBD. IgG seropositivity was greater in those with prior COVID-19, aged 50 years or younger and in females. At 24 weeks after vaccination, 37.4% of participants showed IFN-γ responses to SARS-CoV-2 antigens. T cell IFN-γ release was higher in those with prior COVID-19 and those aged 50 years or less. Highest IFN-γ release was observed to extended genome antigens in individuals both with and without prior COVID-19. Conclusion: We found that IgG seropositivity to both Spike and RBD was affected by prior COVID-19, age and gender. Importantly, seropositive responses persisted up to 24 weeks after vaccination. Persistence of vaccine induced IgG antibodies may be linked to the high seroprevalence observed earlier in unvaccinated individuals. Increased T cell reactivity to Spike and extended genome antigens reflects cellular activation induced by BBIBP-CorV. COVID-19 vaccination may have longer lasting immune responses in populations with a higher seroprevalence. These data inform on vaccination booster policies for high-risk groups.",

keywords = "COVID-19, Immunoglobulin G, Interferons, T-lymphocytes, Vaccination",

author = "Zahra Hasan and Masood, {Kiran Iqbal} and Shama Qaiser and Erum Khan and Areeba Hussain and Zara Ghous and Unab Khan and Maliha Yameen and Imran Hassan and Nasir, {Muhammad Imran} and Qazi, {Muhammad Farrukh} and Memon, {Haris Ali} and Shiza Ali and Sadaf Baloch and Bhutta, {Zulfiqar A.} and Marc Veldhoen and Simas, {J. Pedro} and Mahmood, {Syed Faisal} and Kulsoom Ghias and Rabia Hussain",

note = "Funding Information: We sincerely thank all our study subjects for their kind and valuable participation. Thanks to Ambreen Wasim for assistance with statistical analysis. Also thank Naila Baig‐Ansari and Nausheen Saifullah for assistance in recruitment of study subjects. This study was supported by the Provost's Academic Priorities Fund, Aga Khan University. Thanks to Paula Alves, iBET/ITQB, NOVA University, Portugal for providing recombinant proteins used in this study. MV was supported by the European Union H2020 ERA project (No. 667824—EXCELLtoINNOV). The supporting sources had no involvement in the interpretation of data, writing of the report and decision to submit the manuscript for publication. Funding Information: We sincerely thank all our study subjects for their kind and valuable participation. Thanks to Ambreen Wasim for assistance with statistical analysis. Also thank Naila Baig-Ansari and Nausheen Saifullah for assistance in recruitment of study subjects. This study was supported by the Provost's Academic Priorities Fund, Aga Khan University. Thanks to Paula Alves, iBET/ITQB, NOVA University, Portugal for providing recombinant proteins used in this study. MV was supported by the European Union H2020 ERA project (No. 667824—EXCELLtoINNOV). The supporting sources had no involvement in the interpretation of data, writing of the report and decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.",

year = "2023",

month = sep,

day = "8",

doi = "10.1002/hsr2.1521",

language = "English",

volume = "6",

journal = "Health Science Reports",

issn = "2398-8835",

publisher = "John Wiley & Sons Inc.",

number = "9",

}

Hasan, Z, Masood, KI, Qaiser, S, Khan, E, Hussain, A, Ghous, Z, Khan, U, Yameen, M, Hassan, I, Nasir, MI, Qazi, MF, Memon, HA, Ali, S, Baloch, S, Bhutta, ZA, Veldhoen, M, Simas, JP, Mahmood, SF, Ghias, K & Hussain, R 2023, 'Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: a prospective observational study', Health Science Reports, vol. 6, n.º 9, e1521. https://doi.org/10.1002/hsr2.1521

TY - JOUR

T1 - Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population

T2 - a prospective observational study

AU - Hasan, Zahra

AU - Masood, Kiran Iqbal

AU - Qaiser, Shama

AU - Khan, Erum

AU - Hussain, Areeba

AU - Ghous, Zara

AU - Khan, Unab

AU - Yameen, Maliha

AU - Hassan, Imran

AU - Nasir, Muhammad Imran

AU - Qazi, Muhammad Farrukh

AU - Memon, Haris Ali

AU - Ali, Shiza

AU - Baloch, Sadaf

AU - Bhutta, Zulfiqar A.

AU - Veldhoen, Marc

AU - Simas, J. Pedro

AU - Mahmood, Syed Faisal

AU - Ghias, Kulsoom

AU - Hussain, Rabia

N1 - Funding Information: We sincerely thank all our study subjects for their kind and valuable participation. Thanks to Ambreen Wasim for assistance with statistical analysis. Also thank Naila Baig‐Ansari and Nausheen Saifullah for assistance in recruitment of study subjects. This study was supported by the Provost's Academic Priorities Fund, Aga Khan University. Thanks to Paula Alves, iBET/ITQB, NOVA University, Portugal for providing recombinant proteins used in this study. MV was supported by the European Union H2020 ERA project (No. 667824—EXCELLtoINNOV). The supporting sources had no involvement in the interpretation of data, writing of the report and decision to submit the manuscript for publication. Funding Information: We sincerely thank all our study subjects for their kind and valuable participation. Thanks to Ambreen Wasim for assistance with statistical analysis. Also thank Naila Baig-Ansari and Nausheen Saifullah for assistance in recruitment of study subjects. This study was supported by the Provost's Academic Priorities Fund, Aga Khan University. Thanks to Paula Alves, iBET/ITQB, NOVA University, Portugal for providing recombinant proteins used in this study. MV was supported by the European Union H2020 ERA project (No. 667824—EXCELLtoINNOV). The supporting sources had no involvement in the interpretation of data, writing of the report and decision to submit the manuscript for publication. Publisher Copyright: © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.

PY - 2023/9/8

Y1 - 2023/9/8

N2 - Background and Aims: COVID-19 vaccinations have reduced morbidity and mortality from the disease. Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) have been associated with immune protection. Seroprevalence studies revealed high immunoglobulin G (IgG) antibody levels to SARS-CoV-2 in the Pakistani population before vaccinations. We investigated the effect of BBIBP-CorV vaccination on circulating IgG antibodies and interferon (IFN)-γ from T cells measured in a cohort of healthy individuals, with respect to age, gender, and history of COVID-19. Methods: The study was conducted between April and October 2021. BBIBP-CorV vaccinated participants were followed up to 24 weeks. Antibodies to SARS-CoV-2 Spike protein and its receptor-binding domain (RBD) were measured. IFNγ secreted by whole blood stimulation of Spike protein and extended genome antigens was determined. Results: Study participants with a history of prior COVID-19 displayed a higher magnitude of IgG antibodies to Spike and RBD. IgG seropositivity was greater in those with prior COVID-19, aged 50 years or younger and in females. At 24 weeks after vaccination, 37.4% of participants showed IFN-γ responses to SARS-CoV-2 antigens. T cell IFN-γ release was higher in those with prior COVID-19 and those aged 50 years or less. Highest IFN-γ release was observed to extended genome antigens in individuals both with and without prior COVID-19. Conclusion: We found that IgG seropositivity to both Spike and RBD was affected by prior COVID-19, age and gender. Importantly, seropositive responses persisted up to 24 weeks after vaccination. Persistence of vaccine induced IgG antibodies may be linked to the high seroprevalence observed earlier in unvaccinated individuals. Increased T cell reactivity to Spike and extended genome antigens reflects cellular activation induced by BBIBP-CorV. COVID-19 vaccination may have longer lasting immune responses in populations with a higher seroprevalence. These data inform on vaccination booster policies for high-risk groups.

AB - Background and Aims: COVID-19 vaccinations have reduced morbidity and mortality from the disease. Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) have been associated with immune protection. Seroprevalence studies revealed high immunoglobulin G (IgG) antibody levels to SARS-CoV-2 in the Pakistani population before vaccinations. We investigated the effect of BBIBP-CorV vaccination on circulating IgG antibodies and interferon (IFN)-γ from T cells measured in a cohort of healthy individuals, with respect to age, gender, and history of COVID-19. Methods: The study was conducted between April and October 2021. BBIBP-CorV vaccinated participants were followed up to 24 weeks. Antibodies to SARS-CoV-2 Spike protein and its receptor-binding domain (RBD) were measured. IFNγ secreted by whole blood stimulation of Spike protein and extended genome antigens was determined. Results: Study participants with a history of prior COVID-19 displayed a higher magnitude of IgG antibodies to Spike and RBD. IgG seropositivity was greater in those with prior COVID-19, aged 50 years or younger and in females. At 24 weeks after vaccination, 37.4% of participants showed IFN-γ responses to SARS-CoV-2 antigens. T cell IFN-γ release was higher in those with prior COVID-19 and those aged 50 years or less. Highest IFN-γ release was observed to extended genome antigens in individuals both with and without prior COVID-19. Conclusion: We found that IgG seropositivity to both Spike and RBD was affected by prior COVID-19, age and gender. Importantly, seropositive responses persisted up to 24 weeks after vaccination. Persistence of vaccine induced IgG antibodies may be linked to the high seroprevalence observed earlier in unvaccinated individuals. Increased T cell reactivity to Spike and extended genome antigens reflects cellular activation induced by BBIBP-CorV. COVID-19 vaccination may have longer lasting immune responses in populations with a higher seroprevalence. These data inform on vaccination booster policies for high-risk groups.

KW - COVID-19

KW - Immunoglobulin G

KW - Interferons

KW - T-lymphocytes

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85170044467&partnerID=8YFLogxK

U2 - 10.1002/hsr2.1521

DO - 10.1002/hsr2.1521

M3 - Article

C2 - 37692793

AN - SCOPUS:85170044467

SN - 2398-8835

VL - 6

JO - Health Science Reports

JF - Health Science Reports

IS - 9

M1 - e1521

ER -